Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Currently Reading
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
March 29, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Addressing the Affordability Issue of Novel Treatments
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
April 17, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue
April 22, 2017
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
April 27, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Aimee Tharaldson Highlights Two Key Drugs for 2017

The first drug to treat primary progressive multiple sclerosis and a new drug approved for atopic dermatitis are the 2017 approvals most exciting to Aimee Tharaldson, PharmD, of Express Scripts.


What drugs expected to be approved in 2017 are most exciting to you?

You know it’s interesting, the 2 drugs that I think are going to be key this year, are expected to be approved today. Actually, one drug is Ocrevus. This is going to be the first drug approved to treat primary progression MS. It’s also in development for relapsing forms of MS. So it’s a biologic drug. It’s given every 6 months. In clinical trials for relapsing forms of MS, they compared it to Rebif, and it reduced relapse rates by about 40% compared to Rebif. They looked at it in primary progression MS and it reduced disability progression by about 25% compared to placebo. So it’s a very effective medication.

There is a safety signal to watch for in the primary progressive MS trial. It did cause tumors in 2.3% of patients, which is twice as much as the placebo group. So that will have to be monitored carefully. It may have a box warning concerning this risk.

But watch for Ocrevus today.

And another drug, which we were expecting to be approved tomorrow, just got approved about an hour or so ago: Dupixent, or dupilumab. So this is a biologic drug to treat patients with moderate to severe atopic dermatitis, who aren’t well controlled on currently available topical therapies like glucocorticoids or calcineurin inhibitors, like Protopic or Elidel. So there’s 300,000 or more patients in the United States right now who could be candidates for treatment with Dupixent.

The manufacturer did release pricing. It’s going to be $37,000 per year. So this is a medication that’s going to be used chronically in these patients. Very effective medication. Can be used alone or in combination with topical glucocorticoids. So I don’t know exactly the launch date of that product, but I imagine it will reach the market pretty soon.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up